. Author manuscript; available in PMC: 2009 Dec 1.

Published in final edited form as: J Cardiovasc Pharmacol. 2008 Dec;52(6):500–506. doi: 10.1097/FJC.0b013e31818f5739

Table 1. Baseline demographics, Total and by beta blocker.

Variable	All Subjects (N=30)	Carvedilol (N=15)	Metoprolol (N=15)	P carvedilol vs. metoprolol

Age (yrs)	57.8 ± 15.0	54.8 ± 17.8	60.9 ± 11.3	0.38
Men, n (%)	21 (70)	10 (67)	11 (73)	1.00
White/black/Hispanic	27 /1 / 2	14/0/1	13/1/1	0.89
NYHA FC II/III	27 (90%) / 3 (10%)	15(100 %) / 0(0%)	12(80%) / 3(20%)	0.22
Ischemic heart disease	11 (37%)	5 (33%)	6 (40%)	0.70
Body mass index	30.1 ± 5.1	29.6 ± 5.5	30.6 ± 4.9	0.46
LVEF^* (%), range	34.6% ± 10.1%, 15-55%	34.7 ± 10.1, 15-55%	34.6 ± 10.6, 15-55%	0.93
Background therapy
ACE inhibitor / ARB^**	29 (96.7%)	15 (100%)	14 (93%)	1.0
Furosemide	21 (70%)	11 (73%)	10 (67%)	0.99
Digoxin	15 (50%)	9 (60%)	6 (40%)	0.27
Spironolactone	12 (40%)	6 (40%)	6 (40%)	1.00
Statin	22 (73%)	11 (73%)	11 (73%)	1.00

LVEF: left ventricular ejection fraction

^**

ARB: angiotensin receptor blocker